Several promising approaches are being explored to tackle limited scalability. Biosimilars and generic drugs offer more affordable alternatives to expensive brand-name treatments. Efforts to streamline regulatory processes and enhance manufacturing efficiencies are also underway. Moreover, innovative funding models, such as value-based pricing, could make treatments more accessible without compromising quality.
